RSS Feed
Twitter
Datamonitor estimates 2008 SLE sales of $1.1 billion in the seven major markets. After 50 years without a new drug approval, serious unmet needs persist. Numerous drug candidates have failed to progress beyond Phase III, but innovation in development has led to recent success. Datamonitor forecasts four late-stage pipeline products, which could inject $2.9 billion into the SLE market by 2019. Scope * Segmentation and analysis of the SLE pipeline with in-depth discussion and assessment of key late-stage and recently discontinued drug candidates
* Interactive patient-based forecasts of 4 late-stage pipeline candidates, with a comparison of their relative clinical and commercial attractiveness
* Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
* Focus on R&D trends with recommendations on late-stage development and assessments of past drug failures Highlights Considerable unmet needs remain in SLE, creating significant market opportunity. Late-stage pipeline products offer the potential to address these needs, mainly by reducing side effects. As a result, the SLE market is set to experience strong growth, with four new product launches forecast to create sales of $2.9 billion by 2019. With Phase III success, Benlysta (belimumab) is set to reach the market first and experience rapid uptake, with peak sales of $1.9 billion by 2013. However market potential will remain for pipeline products through both further patient penetration and patient switching. Competition is forecast to decrease Benlysta''s sales to $1.1 billion by 2019. After years of failed SLE trials, the lessons learned are being applied. Recent trial design highlights a shift in thinking, moving from use of solo disease activity indices, to utilization of a composite responder index. Initial results are encouraging, representing a significant advancement in development, but careful interpretation is required. Reasons to Purchase * Gain insight into the recent advances and failures in the SLE pipeline and understand the trends driving development
* Access 10 year patient based forecasts of four late-stage pipeline products and key off-label products in SLE, with interactive assumptions
* Understand the unmet needs in SLE and challenges faced in drug development, plus how each can be addressed Get more information about this report: Pipeline Insight: Systemic Lupus Erythematosus - Turning a corner in drug development Find Market Research Reports Check our Company Profiles and Country Reports Bharat Book Bureau
Email: sandhya@bharatbook.com
Tel: +91 22 27578668
Fax: +91 22 27579131
* Interactive patient-based forecasts of 4 late-stage pipeline candidates, with a comparison of their relative clinical and commercial attractiveness
* Insight and analysis of market potential including commercial opportunity, epidemiology and discussion of unmet needs
* Focus on R&D trends with recommendations on late-stage development and assessments of past drug failures Highlights Considerable unmet needs remain in SLE, creating significant market opportunity. Late-stage pipeline products offer the potential to address these needs, mainly by reducing side effects. As a result, the SLE market is set to experience strong growth, with four new product launches forecast to create sales of $2.9 billion by 2019. With Phase III success, Benlysta (belimumab) is set to reach the market first and experience rapid uptake, with peak sales of $1.9 billion by 2013. However market potential will remain for pipeline products through both further patient penetration and patient switching. Competition is forecast to decrease Benlysta''s sales to $1.1 billion by 2019. After years of failed SLE trials, the lessons learned are being applied. Recent trial design highlights a shift in thinking, moving from use of solo disease activity indices, to utilization of a composite responder index. Initial results are encouraging, representing a significant advancement in development, but careful interpretation is required. Reasons to Purchase * Gain insight into the recent advances and failures in the SLE pipeline and understand the trends driving development
* Access 10 year patient based forecasts of four late-stage pipeline products and key off-label products in SLE, with interactive assumptions
* Understand the unmet needs in SLE and challenges faced in drug development, plus how each can be addressed Get more information about this report: Pipeline Insight: Systemic Lupus Erythematosus - Turning a corner in drug development Find Market Research Reports Check our Company Profiles and Country Reports Bharat Book Bureau
Email: sandhya@bharatbook.com
Tel: +91 22 27578668
Fax: +91 22 27579131
via Posterize
Posts
0 comments:
Post a Comment